** Shares of drug developer Alnylam Pharmaceuticals ALNY.O rise 6.5% to $270 premarket
** On Thursday, US FDA approved ALNY's injectable drug, Amvuttra, to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and deadly heart disease
** Amvuttra was first approved in 2022 to treat nerve damage related to ATTR-CM
** Amvuttra is the first treatment to address both nerve and heart forms of ATTR-CM, working by reducing production of the disease-causing protein
** List price of Amvuttra is $119,351 per prefilled syringe, administered every 3 months, with no planned change for ATTR-CM treatment
** Brokerage Jefferies said it expects Amvuttra's price to decrease over time as prescription volumes rise, with initial impacts likely in the H2 of this year
** ALNY gained 71.4%, in the last 12 months
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.